RegenExtracell BMC®

The Flexible & Reproducible Bone Marrow Concentrate System

What is RegenExtracell BMC ?

BONE MARROW CONCENTRATE (BMC) IS AN AUTOLOGOUS CELL CONCENTRATE FROM BONE MARROW ASPIRATE.

Bone marrow is a liquid tissue rich in a heterogeneous population of mature cells and multipotent stem cells. Among them, the mesenchymal stromal cells (MSC) are the musculoskeletal tissue precursor cells.

These tubes contain a biologically inert separating gel with a specific density that stabilises the physical separation of plasma and mononuclear cell (MNC) fractions from the other cellular elements of the bone marrow aspirate. This allows intraoperative processing of bone marrow aspirate to produce a bone marrow aspirate concentrate that is reimplanted during the same surgical procedure without the need for cell selection and expansion in the laboratory (‘one-step therapy’) (Holton et al., 2016).

More than 80 % of the MSCs are obtained in the resulting cell concentrate. In vitro, these cells form colony-forming fibroblast units (CFU-F), which are capable of undergoing osteogenesis, chondrogenesis and adipogenesis when cultured in their respective specific induction medium. By transferring all the regenerative potential in the bone marrow aspirate to the site of the lesion, the bone marrow aspirate concentrate represents an interesting therapeutic option for treatment.

Since 2003, Regen Lab SA has been committed to the development of a unique expertise for the design and manufa​cturing of high-quality medical devices, intended for cells therapies.

Copyright © 2025 All rights reserved.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

Hyaluronic Acid

Coming Soon

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.